R0-1 50947/PHS HHS/United States[Grants and Funding] - Search Results

Year	Number of Results
2002	8
2003	9
2004	4
2005	5
2006	4
2007	1
2009	2
2010	1
2012	2
2013	3
2014	2
2016	1
2024	0

1

Anderson KC, Shaughnessy JD Jr, Barlogie B, Harousseau JL, Roodman GD. Anderson KC, et al. Hematology Am Soc Hematol Educ Program. 2002:214-40. doi: 10.1182/asheducation-2002.1.214. Hematology Am Soc Hematol Educ Program. 2002. PMID: 12446425 Review.

2

New frontiers in the treatment of multiple myeloma.

Hwang JJ, Ghobrial IM, Anderson KC. Hwang JJ, et al. ScientificWorldJournal. 2006 Dec 6;6:1475-503. doi: 10.1100/tsw.2006.236. ScientificWorldJournal. 2006. PMID: 17160337 Free PMC article. Review.

3

The emerging role of novel therapies for the treatment of relapsed myeloma.

Richardson PG, Hideshima T, Mitsiades C, Anderson KC. Richardson PG, et al. J Natl Compr Canc Netw. 2007 Feb;5(2):149-62. doi: 10.6004/jnccn.2007.0015. J Natl Compr Canc Netw. 2007. PMID: 17335684 Review.

4

Characterization of the MM.1 human multiple myeloma (MM) cell lines: a model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells.

Greenstein S, Krett NL, Kurosawa Y, Ma C, Chauhan D, Hideshima T, Anderson KC, Rosen ST. Greenstein S, et al. Exp Hematol. 2003 Apr;31(4):271-82. doi: 10.1016/s0301-472x(03)00023-7. Exp Hematol. 2003. PMID: 12691914 Free article. Review.

5

Novel biological therapies for the treatment of multiple myeloma.

Richardson PG, Mitsiades CS, Hideshima T, Anderson KC. Richardson PG, et al. Best Pract Res Clin Haematol. 2005;18(4):619-34. doi: 10.1016/j.beha.2005.01.010. Best Pract Res Clin Haematol. 2005. PMID: 16026741 Review.

6

Intracellular NAD⁺ depletion enhances bortezomib-induced anti-myeloma activity.

Cagnetta A, Cea M, Calimeri T, Acharya C, Fulciniti M, Tai YT, Hideshima T, Chauhan D, Zhong MY, Patrone F, Nencioni A, Gobbi M, Richardson P, Munshi N, Anderson KC. Cagnetta A, et al. Blood. 2013 Aug 15;122(7):1243-55. doi: 10.1182/blood-2013-02-483511. Epub 2013 Jul 3. Blood. 2013. PMID: 23823317 Free PMC article.

7

The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival.

Ohguchi H, Hideshima T, Bhasin MK, Gorgun GT, Santo L, Cea M, Samur MK, Mimura N, Suzuki R, Tai YT, Carrasco RD, Raje N, Richardson PG, Munshi NC, Harigae H, Sanda T, Sakai J, Anderson KC. Ohguchi H, et al. Nat Commun. 2016 Jan 5;7:10258. doi: 10.1038/ncomms10258. Nat Commun. 2016. PMID: 26728187 Free PMC article.

8

Moving disease biology from the lab to the clinic.

Anderson KC. Anderson KC. Cancer. 2003 Feb 1;97(3 Suppl):796-801. doi: 10.1002/cncr.11137. Cancer. 2003. PMID: 12548578 Free article.

9

Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo.

Lentzsch S, LeBlanc R, Podar K, Davies F, Lin B, Hideshima T, Catley L, Stirling DI, Anderson KC. Lentzsch S, et al. Leukemia. 2003 Jan;17(1):41-4. doi: 10.1038/sj.leu.2402745. Leukemia. 2003. PMID: 12529658

10

Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications.

Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D, Hideshima T, Treon SP, Munshi NC, Richardson PG, Anderson KC. Mitsiades CS, et al. Oncogene. 2002 Aug 22;21(37):5673-83. doi: 10.1038/sj.onc.1205664. Oncogene. 2002. PMID: 12173037

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

35 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35 results

Results by year